Resource Center
Resource Center
CHAI is proud of the progress we have made, in partnership with governments and other organizations, and with support from our donors, to address health issues in low- and middle-income countries in 2018. As we embark on a new year, we are looking back at some of the highlights from our work in 2018, as...
Read moreSitting and talking with other people living with HIV at a health facility in Uganda, Zane* no longer felt alone. Unlike many of the others there who remained on efavirenz (EFV), he had recently switched to a new treatment regimen that includes dolutegravir (DTG) and could not believe how much better he felt. On DTG,...
Read moreA clear understanding of the complex, ever-changing antiretroviral (ARV) and diagnostic markets in low- and middle-income countries is critical for all stakeholders in the HIV space. To address this need, CHAI publishes an annual HIV market report for public consumption based on aggregated market intelligence from our programmatic work in over 30 countries. We are...
Read moreWe are delighted to announce the joint launch of a partnership to speed up development and introduction of optimized pediatric formulations of dolutegravir for children living with HIV in resource-limited settings. The new initiative includes an incentive program and is a key feature of Unitaid’s US$34 million Optimal Antiretroviral (ARV) grant to CHAI. The optimal...
Read moreThis World AIDS Day, we celebrate the tremendous progress that has been made in response to the HIV/AIDS epidemic, with more than 20 million people living with HIV accessing life-saving antiretroviral treatment (ART) as of today. The incredible scale up of ART in developing countries, with affordable generic drugs widely available and the majority of...
Read moreNegotiated pricing agreements have lowered costs and will improve access to quality treatment for people living with HIV New York – A breakthrough pricing agreement has been announced which will accelerate the availability of the first affordable, generic, single-pill HIV treatment regimen containing dolutegravir (DTG) to public sector purchasers in low- and middle-income countries...
Read moreNational HIV treatment programs are preparing for big shifts in their national treatment guidelines and patient regimens. The World Health Organization’s (WHO) 2016 guidelines included a number of antiretroviral (ARV) medications that are more effective, tolerable and affordable (some of which are now available), in addition to optimal pediatric formulations which improve upon limited treatment...
Read moreLondon, 30 November 2016 – UNITAID and the Clinton Health Access Initiative (CHAI) today announced a three-year project to speed the introduction of new, optimal HIV drugs, and make them more available and affordable. The US$34 million investment is expected to be a boon for adults and children living with HIV who receive treatments that...
Read moreAurobindo Pharma Limited is pleased to announce the tentative approval of Dolutegravir 50mg from US Food & Drug Administration (USFDA) for the treatment of HIV. This important milestone marks the first FDA approval of a generic version of Dolutegravir (DTG), an integrase strand transfer inhibitor recommended for use in treatment-naïve patients by the US...
Read moreThese agreements have the potential to increase access to state-of-the-art HIV treatment regimens for people living with HIV in low- and middle- income countries.
Read more